A Systematic Review of Genotoxicity and Mutagenicity Affecting Reproductive and Neurocognitive Health: Bridging

Rajat Ramesh Pithadia1

  • 1Department of Forensic Science, Vivekananda Global University, Jaipur, India.

Insights

This review links genotoxic exposures to multisystem health issues, highlighting research gaps and prioritizing future studies on emerging contaminants and vulnerable populations. Actionable insights are provided for regulators and health professionals.

Area of Science:

  • Toxicology and Genetics
  • Reproductive Medicine and Neuroscience

Background:

  • Emerging scholarly consensus on genotoxic exposures and multisystem health dysfunctions.
  • Need for an interdisciplinary approach bridging toxicology, genetics, reproductive medicine, and neuroscience.

Purpose of the Study:

  • Examine the mechanistic linkage between genotoxic exposures and multisystem health dysfunctions.
  • Identify trends in genotoxicity research and its causal relationship with reproductive and neurocognitive health outcomes.
  • Bridge traditional siloed research domains.

Main Methods:

  • Systematic literature review (B-SLR) of 200 peer-reviewed publications (2021-2025).
  • SPAR4-SLR protocol with ROBINS-I adaptation for quality appraisal and publication bias assessment.
  • Bibliometric analysis, thematic mapping, citation network analysis, and mechanistic pathway modeling using Biblioshiny software.

Main Results:

  • Identified eight research clusters: DNA mutations, reprotoxicity, neurotoxicity, transgenerational/epigenetic transmission, bioaccumulation, emerging contaminants, mechanistic pathways, and regulatory applications.
  • Highlighted a critical knowledge gap: dominance of animal studies (97%) over human epidemiological studies (3%), leading to a 20-30 year translation lag.
  • Prioritized five research agendas: comparative potency of emerging contaminants, epigenetic mechanisms, mixture effects, remediation strategies, and vulnerability of sensitive populations.

Conclusions:

  • The research is ready for policy translation, with a regulatory opportunity closing by 2027-2028.
  • Provides actionable intelligence for funding agencies, international regulators, occupational health professionals, pharmaceutical developers, and health practitioners.
  • An integrated mechanistic framework is proposed to enable coordinated multistakeholder action.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...